FeesSafety
Pluang+

Recursion Pharma shares rise 4% after FDA aligns on Phase 3 trial for AI-driven drug REC-4881.

Market News
19 Nov 2026, 05:20 WIB
Josh Kohn-Lindquist
View Source
Bullish
Recursion Pharma shares rise 4% after FDA aligns on Phase 3 trial for AI-driven drug REC-4881.

Recursion Pharmaceuticals' stock increased by 3.86% following FDA alignment on the Phase 3 trial design for its AI-enabled drug REC-4881 targeting familial adenomatous polyposis, a disease with no current approved treatments. The FDA accepted a primary endpoint that could shorten and reduce the cost of the trial. This advancement positions REC-4881 as one of the first AI-driven treatments moving into late-stage trials, representing a potential $15 billion market. However, the Phase 3 trial will only begin in late 2027, requiring investors to be patient and cautious.

Recursion Pharmaceuticals trades at USD 2.85 on Pluang as of Nov 19, 2026 06:11 WIB, up 4.78% in one day. The stock shows strong buying interest with 63% of orders as buys. Its market cap stands at $1.71 billion, reflecting steady investor attention amid the Phase 3 trial news.

More News (RXRX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App